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Key Clinical Message
X-linked adrenoleukodystrophy may present with a deceptively mild phenotype,
even in adult males. Tight collaboration between clinicians, geneticists, bio-
chemists, and other specialists is increasingly required for clarification of diag-
nosis in cases with atypical presentation.
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Introduction
X-linked adrenoleukodystrophy (X-ALD) [1] was initially
known as a usually fatal progressive cerebral leukodystro-
phy of childhood, affecting boys. Later on, it was recog-
nized that this childhood form occurs in only about one-
third of males (hemizygotes). However, males who survive
into adulthood develop a picture of adrenal and testicular
insufficiency, myelopathy and peripheral neuropathy
known as adrenomyeloneuropathy (AMN). Onset of AMN
in males is usually in the 3rd or 4th decade [1]. Recent
research [2–4] has shown that a large proportion of AMN
males develop cerebral demyelination during adulthood.
Furthermore, a phenotype characterized by myeloneuropa-
thy is found in most females (heterozygotes) beyond the
age of 50–60 [3, 5, 6]. Therefore, a current view of X-ALD
is that a more severe course, with age-dependent pene-
trance, is seen in both male and female subjects.
A few elderly males with mild symptoms have been
reported [7–10], but descriptions detailing symptoms
and features in this subset of patients are lacking. The
existence of such phenotypes is important, both for the
counseling of young males diagnosed with X-ALD on
the basis of genetic studies, and for the further investiga-
tion of X-ALD kindreds searching for affected males
who may form a link to other affected branches of the
pedigree.
Case Report
A 61-year-old male patient of Norwegian ethnicity was
evaluated for Parkinson’s disease, when clinical examina-
tion disclosed subtle signs of myelopathy. Elevated levels
of very long-chain fatty acids (VLCFAs) had raised the
possibility of X-ALD as a differential diagnosis. A genetic
variant of uncertain significance [11] previously not
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reported in the X-ALD database (www.x-ald.nl) had been
found in the ABCD1 gene.
The patient had first been investigated at age 48 for fre-
quent fasciculations in the legs. Neurophysiologic studies
at that time suggested a slight sensorimotor peripheral
neuropathy. At age 51, Babinski signs were demonstrated
bilaterally, without any other signs of pyramidal tract dys-
function. However, during the subsequent years, he devel-
oped a slight, but definite, tetraspasticity and symmetrical
hyperreflexia, with subjective symptoms of muscle stiff-
ness, gait difficulties, and unsteadiness. Yet, his motor
function was still good; he retained the ability to run and
take strenuous hikes in the mountains.
From age 57, he developed asymmetric bradykinesia
and rigidity, a clinical picture typical of Parkinson’s dis-
ease. Multisystem atrophy of the Parkinsonian type could
be suspected; however, there was an excellent response to
levodopa therapy. The patient’s function returned to near
normal levels: He was fully ambulatory without aids,
played basketball matches and worked full time in an
office.
At the time of the study, Spastic Paraplegia Rating
Scale [12] score was 4/52 (0/1/0/0/0/0/2/1/0/0/0/0/0)
points. The Expanded Disability Status Scale [13] score
was 3.0 (normal ambulation, FS score 3 for sensory func-
tions, FS score 1 for pyramidal functions, bladder/bowel
functions and spasticity, others 0).
The patient’s family history was negative for X-ALD,
even when searching for minor details suggesting mild
myelopathy or Addisonism in his mother or other ances-
tors. His father had typical levodopa-responsive Parkin-
son’s disease, negative for LRRK2 mutations. The
patient’s brother died at age 44, without any history
indicating myelopathy or Addisonism. The patient’s only
daughter was clinically healthy at age 32.
Due to the scarcity of symptoms typical for X-ALD,
the lack of family history and the absence of evidence that
the genetic variant was pathogenic, we were uncertain
whether the patient should be classified as having X-ALD.
He therefore underwent further investigations.
Investigations
The patient underwent thorough clinical, paraclinical,
(Table 1) and biochemical (Tables 2 and 3) work-up.
MRI of brain and spinal cord showed no signs of
demyelination. Standard neurophysiologic studies demon-
strated a progressive, moderate sensorimotor polyneu-
ropathy of the lower extremities, with predominantly
axonal changes. Neurophysiologic small nerve fiber stud-
ies were mostly normal; however, skin biopsy [14]
revealed a loss of intraepidermal small nerve fibers.
The patient had no symptoms or clinical signs suggest-
ing primary adrenal or testicular insufficiency, except
scanty scalp hair, also seen in his father. Endocrinologic
measurements in blood were normal, including ACTH
stimulation test to rule out subclinical adrenal insuffi-
ciency. VLCFA measurements and enzymatic studies were
performed in a diagnostic setting in cultured fibroblasts
grown from a skin biopsy taken at age 60; the findings
were consistent with X-ALD.
Individual exons with flanking intron sequences of the
ABCD1 gene were amplified from DNA extracted from
EDTA-containing blood. The sequencing products were
Table 1. Paraclinical studies in adult male patient with mild X-ALD phenotype.
Modality
Age at
examination Results
CSF studies – Normal cell count and protein level, no OCBs
MRI1 of brain and spinal cord 61 No sign of demyelination or damage to the long tracts. Visual impression of slender thoracic cord.
Loes score 0
Brain SPECT using DaTscan 58 Asymmetrically reduced signal intensity in the basal ganglia, more pronounced on the right side,
consistent with PD
EMG and NCV studies 61 Moderate sensorimotor peripheral neuropathy in lower extremities, predominantly axonal changes.
Chronic neurogenic changes on EMG
SNF studies 61 Galvanic skin response normal in hands and feet. Normal heart rate variability with heavy
breathing. Elevated threshold for heat sensitivity on left foot, otherwise normal thermal sensitivities
IENFD measurements 61 2.1/mm (normal values (age and gender adjusted): ≥4.9)
CSF, cerebrospinal fluid; OCBs, oligoclonal bands; SPECT, single photon emission computed tomography; DaTscan, ioflupane (123I); PD, Parkinson’s
disease; EMG, electromyography; NCVs, nerve conduction velocities; SNF, small nerve fiber; IENFD, intraepidermal nerve fiber density. Loes score
is a grading scale for extent and severity of demyelinating lesions in MRI imaging of the brain in X-linked adrenoleukodystrophy, range 0 (normal)
to 34 (most severe).
1The following MRI sequences were performed: Brain: T1, T1 with MRI contrast medium (Gadolinium), T2, FLAIR and diffusion-weighted imaging
(DWI) sequences. Spinal cord: T1, T2, short tau inversion recovery (STIR) and DWI sequences.
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run on a Genetic Analyzer 3730 (Applied Biosystems, Fos-
ter City, California, USA) and analyzed using Secscape
version 2.6 software (Applied Biosystems). The sequence
disclosed a previously unreported missense variant of
uncertain significance in exon 3, c.1205T>A (p.Ile402Asn)
using the following primers for sequencing exon 3: For-
ward 50-ATTTGCAGAAGAGCCTCGCC-30 and Reverse
50-TGCAGGGAGAGAAGCATGGC-30. The variant was
not found in exomes from 61,846 unrelated individuals in
the Exome Aggregation Consortium Cambridge, MA
(URL: http://exac.broadinstitute.org) October 2014 (coor-
dinates: X:153001689T/A). Another missense variant in
the ABCD1 gene (c.1202G>A, p.Arg401Gln) causing a
shift in the neighboring position in the ALDP protein, is
reported as pathogenic (www.x-ald.nl). Prediction tools
indicated that the variant was likely to be pathogenic
(SIFT: Deleterious, Mutation Taster: Disease-causing).
MLPA for detection of larger deletions and duplications
(MLPA kit P049; MRC-Holland, Amsterdam, The Nether-
lands) was negative.
The ABCD1 variant was retrieved in the patient’s
healthy daughter. She was found to have elevated VLCFA
levels, consistent with the heterozygous presymptomatic
state of X-ALD.
To study the consequences of the mutation, enzymatic
studies in cultured fibroblasts were performed, showing
elevated C26:0 levels and impaired peroxisomal b-oxida-
tion using C26:0 as a substrate (Table 3). Immunofluores-
cence studies of cultured fibroblasts (Fig. 1) showed
normal staining using antibodies raised against catalase, a
peroxisomal matrix enzyme. Staining using monoclonal
antibodies raised against the ALD protein (ALDP) showed
a mosaic pattern with most cells without ALDP staining,
but also cells with ALDP staining.
Discussion
This patient presented a clinical picture of myelopathy
and peripheral neuropathy, consistent with AMN, but
much milder than expected in AMN males at the age of
61. The biochemical findings in blood and cultured
fibroblasts, and the retrieval of the patient’s mutation in
his daughter (who also had elevated VLCFAs), confirmed
this as a mild, but definite, X-ALD phenotype. In the
classification of Norwegian X-ALD subjects presented pre-
viously, he would have been put in the “SIGNS” category
[3].
The mildness of the myelopathy, the absence of endo-
crine dysfunction (adrenal failure being a hallmark of
Table 2. Laboratory studies in adult male patient with mild X-ALD
phenotype.
Assay Results Unit
Reference
values
Endocrinologic assays
s-cortisol 517 nmol/L 138–690
p-ACTH 6.4 pmol/L <10.2
ACTH stimulation test See legend
s-cortisol pre-stimulation 521 nmol/L
s-cortisol at 30 min 802 nmol/L
s-cortisol at 60 min 849 nmol/L
s-testosterone 12.4 nmol/L 8.0–35.0
s-SHBG 46 nmol/L 15–90
Immunological assays
Anti-ENA ELISA Negative – Negative
s-VGKC autoantibodies <85 pmol/L <85
21OH-autoantibodies <0.03 Arbitrary index <0.10
VLCFA studies
In serum
C22:0 17.7 mg/L 10.1–24.5
C24:0 30.6 mg/L 7.9–22.8
C26:0 1.02 mg/L <0.3
C24:0/C22:0 ratio 1.73 – 0.81–0.96
C26:0/C22:0 ratio 0.058 – 0.010–0.018
In cultured fibroblasts
C22:0 2.13 lmol/g protein 3.84–10.20
C24:0 8.56 lmol/g protein 7.66–17.66
C26:0 1.05 lmol/g protein 0.18–0.38
C24:0/C22:0 ratio 4.02 – 1.55–2.30
C26:0/C22:0 ratio 0.50 – 0.03–0.07
X-ALD, X-linked adrenoleukodystrophy; s-, serum; p-, plasma; ACTH,
adrenocorticotrophic hormone; SHBG, sex hormone-binding globulin;
ENA, extractable nuclear antigens (includes anti-dsDNA, anti-SmD,
anti-RNP, anti-SSA/Ro52, anti-SSA/Ro60, anti-SSB/La, anti-CENP-B,
anti-Scl70, anti-Jo-1, anti-Fibrillarin, anti-Mi-2, anti-PCNA, anti-Riboso-
mal P, anti-RNA Pol III and anti-PM-Scl100); ELISA, enzyme-linked
immunosorbent assay; VGKC, voltage-gated potassium channels;
21OH, 21-hydroxylase; VLCFA, very long-chain fatty acids; C22:0,
C24:0 and C26:0 are saturated unbranched fatty acids with 22, 24
and 26 carbon atoms, respectively. The rapid ACTH stimulation test is
performed by intravenous injection of 250 lg Synacthen (ACTH),
with measurements of s-cortisol at 0, 30 and 60 min. A normal
response is poststimulation values of ≥500 nmol/L, and a rise from
baseline of ≥200 nmol/L.
Table 3. Enzymatic studies in cultured fibroblasts from adult male
patient with mild X-ALD phenotype.
Assay Results Unit
Reference
values
Phytanic acid a-oxidation activity 33 pmol/(h.mg
protein)
28–95
Peroxisomal b-oxidation activity
with C26:0 as a substrate
243 pmol/(h.mg
protein)
800–2040
Peroxisomal b-oxidation activity
with pristanic acid as a
substrate
902 pmol/(h.mg
protein)
790–1690
X-ALD, X-linked adrenoleukodystrophy.
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X-ALD), and the predominance of Parkinsonism in the
clinical picture, contributed to a delay in the diagnosis of
X-ALD. Failure to detect X-ALD may hamper the identifi-
cation of affected relatives, thereby missing opportunities
for early detection of Addisonism in boys and follow-up of
boys in order to provide hematopoietic stem cell transplan-
tation in case of cerebral leukodystrophy [15] and genetic
counseling.
We are not aware that Parkinsonism has been reported
as a phenotype of ABCD1 mutations. Multisystem atrophy
of the striatonigral form (in which a combination of
Parkinsonism and pyramidal signs may be seen) was unli-
kely, given the excellent response to levodopa therapy. The
most likely interpretation is that Parkinsonian features in
this patient were unrelated to the ABCD1 mutation.
We remain uncertain as to how to classify the long-
standing symptom of fasciculations in the legs. The
patient did not fit with criteria for the cramps-fascicula-
tion syndrome or amyotrophic lateral sclerosis. Fascicula-
tions may be seen in many hereditary neurological
disorders, and may remain an unspecific finding [16]. It
is possible that his symptoms might be due to instability
of peripheral motor nerves due to his slowly developing
AMN, yet this remains speculative.
The lack of genotype–phenotype correlations in X-ALD
has been emphasized in the literature [17]. However, dif-
ferentiation must be made between two aspects of pheno-
type evolution in X-ALD: one aspect is whether or not
the male patient will develop cerebral ALD, in childhood
or later on [2, 4]. Another aspect is the age at onset and
rate of progression of AMN. These elements are not nec-
essarily linked, as the cerebral leukodystrophy of X-ALD
is partly inflammatory in nature, and possibly related to
external factors like head trauma [18], whereas the
myelopathy is due to slow axonal degeneration [19].
Unknown genetic factors may be partly responsible for
the mild AMN phenotype seen in this patient. However,
family counseling must for the time being assume that his
descendants run the same risk as usual of developing
symptomatic myelopathy (in females) and cerebral
leukodystrophy (in boys).
Our understanding of the natural history of X-ALD is
currently evolving [19]. The slowly progressive myeloneu-
ropathy could be the basic phenotype, affecting most or
all genetically affected subjects, whereas the devastating
cerebral demyelination may be an epiphenomenon, possi-
bly triggered in part by external factors. In this regard,
factors determining the severity of the myeloneuropathy,
in terms of age at onset and rate of progression, may be
important for our understanding of the disease. Patients
with very mild or very severe phenotypes may provide
important clues.
About 700 unique mutations have been described in
the ABCD1 gene (www.x-ald.nl). Most families have their
(A) (B)
(C) (D)
Figure 1. Immunofluorescence microscopy analyses with monoclonal antibodies against adrenoleukodystrophy protein (ALDP) (EUROMEDEX,
ALD-ID6-AS). ALDP immunofluorescence microscopy analyses show the presence of ALDP in the peroxisomal membrane in control fibroblasts
(punctate pattern, positive) (A), the absence of ALDP in the peroxisomal membrane in fibroblasts from an X-ALD patient without ALDP expression
(negative) (B), and a mosaic pattern with most cells without peroxisomal ALDP staining (negative), but some cells with peroxisomal ALDP staining
(positive) in the patient (C and D). p, positive; n, negative.
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own, “private” mutation [17]. Furthermore, de novo
mutations may be more common than previously
reported [3]. Therefore, new patients will frequently pre-
sent with a negative family history, and with a mutation
of undecided pathogenicity. In this patient, the clinical
picture was atypical for X-ALD, and the ABCD1 mutation
was a previously unreported variant of uncertain signifi-
cance. This is a situation clinicians may encounter more
often, as sequencing of genes, exomes, and genomes
becomes more widespread. Such a variant should not be
used as the sole basis of clinical decision making; as illus-
trated by this report, thorough studies may be necessary
to verify that the mutation is pathogenic. In this patient,
the rare disorder of X-ALD was masked by the more
common Parkinson’s disease, a reminder that rare disor-
ders may occur together with more common ones.
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